IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER (IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER).
Replacement of fluid and electrolytes. Dextrose provides caloric support and may prevent ketosis.
| Metabolism | Dextrose is metabolized via glycolysis to pyruvate, entering the citric acid cycle; electrolytes are distributed and excreted renally. |
| Excretion | Electrolytes (sodium, potassium, magnesium, chloride, acetate) are primarily eliminated via renal excretion, with >90% of an administered dose excreted unchanged in urine depending on renal function. Dextrose is fully metabolized to carbon dioxide and water, with no renal excretion of intact dextrose under normal conditions. |
| Half-life | Sodium and chloride have no defined elimination half-life as they are homeostatically regulated; dextrose's terminal elimination half-life is approximately 1.5-2.5 hours in healthy individuals, reflecting insulin-mediated clearance. Clinical context: Half-life of dextrose is prolonged in diabetes or renal impairment. |
| Protein binding | Electrolytes in IONOSOL T AND DEXTROSE 5% are minimally protein-bound (<10%). Sodium and chloride have negligible binding; potassium, magnesium, and acetate are not significantly bound to plasma proteins. |
| Volume of Distribution | Electrolytes distribute throughout total body water (~0.6 L/kg in adults). Dextrose initially distributes into extracellular fluid (0.2 L/kg) but is rapidly taken up by cells. The apparent volume of distribution for administered electrolytes approximates 0.45-0.75 L/kg, reflecting their distribution in body water compartments. |
| Bioavailability | Intravenous administration yields 100% bioavailability for all components. No other relevant routes of administration exist for this solution. |
| Onset of Action | Onset of electrolyte repletion and volume expansion occurs within minutes of intravenous administration. Dextrose's effect on blood glucose elevation is observed within 1-2 minutes following infusion. |
| Duration of Action | Duration of electrolyte and fluid effects depends on infusion rate and renal function, typically lasting 1-4 hours after a single dose. Dextrose effect on blood glucose lasts 1-2 hours post-infusion, correlating with insulin response. |
Intravenous infusion. Rate and volume determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult dose: 1000-2000 mL per 24 hours, administered at a rate of 50-125 mL/hour, adjusted based on patient status.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in oliguric or anuric patients (GFR < 15 mL/min). Use with caution in renal impairment: reduce infusion rate to avoid fluid overload. For GFR 15-30 mL/min, administer at minimum necessary rate; monitor potassium and phosphate levels. |
| Liver impairment | No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte disturbances. Monitor serum electrolytes and fluid status. |
| Pediatric use | Intravenous infusion at a rate of 5-20 mL/kg/hour, adjusted based on age, weight, and clinical need. Do not exceed 100 mL/kg/day in neonates and infants. Use with caution in children due to electrolyte content. |
| Geriatric use | Use with caution due to decreased renal function and higher risk of fluid overload. Start at lower infusion rates (e.g., 25-50 mL/hour) and titrate based on response. Monitor serum electrolytes and renal function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER (IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | Ionosol T and Dextrose 5% components are normal constituents of breast milk. No specific M/P ratio available. Administration is considered compatible with breastfeeding as it is used to correct deficits; however, monitor infant for electrolyte imbalances if maternal therapy is prolonged. |
| Teratogenic Risk | Ionosol T and Dextrose 5% is an electrolyte and carbohydrate solution. No teratogenic effects are expected from the components at therapeutic doses. However, during pregnancy, administration may be necessary to correct fluid and electrolyte imbalances. There are no adequate studies in pregnant women, and it should be used only if clearly needed. In the first trimester, avoid use unless benefits outweigh risks. In the second and third trimesters, use cautiously as dextrose may affect maternal glucose levels. |
■ FDA Black Box Warning
Not for use in patients with known hypersensitivity to any component. Solutions containing dextrose may cause hyperglycemia; use with caution in diabetes mellitus. Do not administer unless solution is clear and container undamaged.
| Serious Effects |
["Hypersensitivity to any component","Clinically significant hyperglycemia","Severe fluid overload or oliguria","Patients with renal impairment requiring dialysis"]
| Precautions | ["Monitor serum electrolytes and glucose levels","Risk of fluid overload in patients with cardiac or renal impairment","Hyperglycemia in patients with diabetes mellitus","Avoid rapid or excessive infusion","Use with caution in patients with severe electrolyte disturbances","Not for use in patients with significant renal impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, blood glucose, fluid balance, and renal function. Assess fetal well-being (heart rate, growth) if prolonged therapy is needed due to maternal condition. Observe for signs of fluid overload in mother and fetus. |
| Fertility Effects | No known effects on fertility. The solution is not expected to impair reproductive function. |